April 17 (Reuters) - Abbott Laboratories ( ABT ) beat

Wall Street estimates for quarterly profit on Wednesday and

raised the lower end of its forecast, as robust demand for

medical procedures boosted sales of its devices, including its

glucose-monitoring products.

On an adjusted basis, the company reported first-quarter

profit of 98 cents per share, compared with analysts' estimate

of 95 cents per share, according to LSEG data.

The company now expects a full-year profit of $4.55 to $4.70

per share, raising the lower end from $4.50 per share. Analysts

were expecting a profit of $4.60 per share.